The stock may react positively to strong 2026 guidance and upcoming regulatory catalysts, particularly the July 2026 PDUFA decision. Traders should monitor prescription trends in Q1 2026 to confirm recovery from prior supply disruptions and watch for data readouts from MONARCH (MASH) and BELLA (ovarian cancer) trials later this year.
Price Chart
Executive Summary
Corcept Therapeutics reported full-year 2025 revenue of $761.4 million, a 12.8% increase from 2024, driven by strong demand in its Cushing's syndrome business despite supply constraints. However, net income declined 29.4% to $99.7 million due to higher operating expenses. The company issued bullish 2026 revenue guidance of $900–$1,000 million, representing 18–32% growth, and highlighted key upcoming catalysts including a July 2026 PDUFA date for relacorilant in ovarian cancer and data readouts from multiple late-stage trials.
Key Financial Metrics
Key Facts
- 2025 revenue: $761.4 million (up 12.8% YoY from $675.0 million)
- 2025 net income: $99.7 million (down 29.4% YoY from $141.2 million)
- 2025 diluted EPS: $0.82 (down 33.3% YoY from $1.23)
- Full-year 2026 revenue guidance: $900–$1,000 million (18–32% growth)
- Cash and investments: $532.4 million at year-end 2025
- PDUFA date for relacorilant in platinum-resistant ovarian cancer: July 11, 2026
- ROSELLA trial met dual endpoints with 35% reduction in risk of death
- Phase 3 trial of dazucorilant in ALS planned for mid-2026
Financial Impact
Revenue growth of $86.4 million in 2025, but net income down $41.5 million. 2026 guidance implies $138.6–$238.6 million revenue increase.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Cushing's syndrome | $761.4M | +12.8% |
Risk Factors
- Declining profitability despite revenue growth
- FDA approval uncertainty for relacorilant in Cushing's syndrome after Complete Response Letter
- Execution risk in transitioning to new specialty pharmacy and scaling operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-011080 |
| Document: cort-20260224.htm | 0001628280-26-011080 |
| Document: 0001628280-26-011080-index-headers.html | 0001628280-26-011080 |
| Document: 0001628280-26-011080-index.html | 0001628280-26-011080 |
| Document: 0001628280-26-011080.txt | 0001628280-26-011080 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 28, 2026 5w ago | Insider Cluster | $113.88 $115.63 | ▲ +1.54% | ▲ +1.28% | $116.49 (+2.29%) |
Aug 28, 2026 5w ago | Insider Cluster | $113.88 $116.10 | ▲ +1.95% | ▲ +1.44% | $116.49 (+2.29%) |
Aug 27, 2026 5w ago | Insider Cluster | $116.93 $117.00 | ▲ +0.06% | ▲ +0.16% | $116.49 (−0.38%) |
Aug 20, 2026 6w ago | Insider Cluster | $121.05 $114.86 | ▼ −5.11% | ▼ −5.11% | $116.49 (−3.77%) |
Aug 18, 2026 6w ago | Insider Cluster | $118.10 $111.85 | ▲ +5.29% | ▲ +4.30% | $116.49 (+1.36%) |
Aug 12, 2026 7w ago | Insider Cluster | $112.18 $114.92 | ▲ +2.44% | ▲ +4.34% | $116.49 (+3.84%) |
Aug 12, 2026 7w ago | Insider Cluster | $112.18 $114.92 | ▲ +2.44% | ▲ +4.34% | $116.49 (+3.84%) |
Aug 6, 2026 8w ago | Insider Cluster | $110.77 $111.62 | ▲ +0.77% | ▲ +1.16% | $116.49 (+5.16%) |
Aug 5, 2026 8w ago | Insider Cluster | $107.95 $112.80 | ▲ +4.49% | ▲ +3.89% | $116.49 (+7.91%) |
Jul 23, 2026 10w ago | Court Ruling | $96.66 $121.05 | ▲ +25.23% | ▲ +21.92% | $116.49 (+20.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access